These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 9563207)

  • 1. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
    Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
    Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
    Gawel M; Aschoff J; May A; Charlesworth BR;
    Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zolmitriptan provides effective migraine relief in adolescents.
    Linder SL; Dowson AJ
    Int J Clin Pract; 2000 Sep; 54(7):466-9. PubMed ID: 11070573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and tolerability of rizatriptan wafers in migraine.
    Cady R; Crawford G; Ahrens S; Hairwassers D; Getson A; Visser WH; Lines C;
    MedGenMed; 2001 Jun; 3(3):1. PubMed ID: 11549974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
    Visser WH; Winner P; Strohmaier K; Klipfel M; Peng Y; McCarroll K; Cady R; Lewis D; Nett R;
    Headache; 2004 Oct; 44(9):891-9. PubMed ID: 15447698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
    Chen LC; Ashcroft DM
    Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
    Zagami AS
    Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zolmitriptan.
    Can Fam Physician; 1999 Jun; 45():1491-4, 1497-501. PubMed ID: 10386213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
    Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
    Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine.
    Natarajan S; Jabbour JT; Webster CJ; Richardson MS
    Headache; 2004; 44(10):969-77. PubMed ID: 15546259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
    Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
    Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
    Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
    Allais G; Acuto G; Cabarrocas X; Esbri R; Benedetto C; Bussone G
    Neurol Sci; 2006 May; 27 Suppl 2():S193-7. PubMed ID: 16688629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.